Key Takeaways:
MediPharm Labs Corp. said its Phase II LiBBY trial met the primary endpoint, showing a statistically significant reduction in agitation among advanced dementia patients.
"The results represent an important milestone for patients and the advancement of cannabinoid-based medicines," Greg Hunter, Interim CEO and CFO of MediPharm Labs, said.
The randomized, double-blind, placebo-controlled study evaluated MediPharm's proprietary oral cannabinoid formulation combining THC and CBD. Benefits were observed as early as two weeks and sustained throughout the 12-week treatment period, as measured by the Cohen-Mansfield Agitation Inventory. Supportive findings from the open-label extension phase demonstrated durability of response over time.
Approximately 50% of people diagnosed with Alzheimer's or other dementias receive hospice care at end of life, and more than 70% of those are prescribed psychiatric medications for agitation, according to the Alzheimer's Clinical Trial Consortium. Current treatments — antipsychotics, sedatives and opiates — often cause undesirable side effects, highlighting the need for new options.
The LiBBY study is led by investigators at the Keck School of Medicine of the University of Southern California and funded by the National Institute on Aging, part of the NIH, with additional funding from the Alzheimer's Association. The study was conducted through the Alzheimer's Clinical Trials Consortium and coordinated by the USC Epstein Family Alzheimer's Therapeutic Research Institute.
MediPharm developed and manufactured the proprietary formulation used in the study and supplied clinical trial materials into the US through a regulated cross-border supply chain. The company retains ownership of the formulation and related intellectual property and has rights to use study data for future regulatory submissions and patent filings. The company is reviewing the full results and evaluating potential next steps, including possible regulatory activities, additional clinical development and potential strategic collaborations.
The positive Phase II data supports MediPharm's pharmaceutical-grade cannabinoid platform and could open the door to regulatory discussions with the FDA. Investors will watch for the company's next steps on a potential Phase III program and any partnership interest from larger pharmaceutical companies.
This article is for informational purposes only and does not constitute investment advice.
